Answering human papillomavirus vaccine concerns; a matter of science and time
1 The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria 3010, Australia
2 Research Centre for Injury Studies, Flinders University, Bedford Park, South Australia 5042, Australia
3 SMART Infrastructure Facility, University of Wollongong, New South Wales 2522, Australia
Infectious Agents and Cancer 2013, 8:22 doi:10.1186/1750-9378-8-22Published: 12 June 2013
Since the introduction of the HPV vaccine, questions have been asked about its efficacy in preventing cancer linked with HPV. Concerns about the HPV vaccine safety profile have also been raised. This paper highlights the rapidly growing body of evidence (including clinical trials and post-marketing surveillance) illustrating both the safety of the HPV vaccine, through a detailed investigation of reported adverse events, and its efficacy in reducing both HPV infections rates and the resulting drop in cervical lesions, which have been demonstrated to be good predictors of cervical cancer risk.